Synonym
KT 182; KT182; KT-182;
IUPAC/Chemical Name
(4-(3'-(hydroxymethyl)-[1,1'-biphenyl]-4-yl)-1H-1,2,3-triazol-1-yl)(2-phenylpiperidin-1-yl)methanone
InChi Key
GICNKPZHUCVFNM-UHFFFAOYSA-N
InChi Code
InChI=1S/C27H26N4O2/c32-19-20-7-6-10-24(17-20)21-12-14-22(15-13-21)25-18-31(29-28-25)27(33)30-16-5-4-11-26(30)23-8-2-1-3-9-23/h1-3,6-10,12-15,17-18,26,32H,4-5,11,16,19H2
SMILES Code
OCC1=CC=CC(C2=CC=C(C=C2)C3=CN(N=N3)C(N4CCCCC4C5=CC=CC=C5)=O)=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
KT182 is a potent and selective inhibitor of α/β-hydrolase domain containing 6 (ABHD6), with an IC50 of 0.24 nM in Neuro2A cells.
In vitro activity:
In cultured neurons, KT182 attenuated NMDA-stimulated excitotoxicity and mitochondrial calcium overload.
Reference: Neuropharmacology. 2018 Oct;141:181-191. https://pubmed.ncbi.nlm.nih.gov/30171986/
In vivo activity:
A twofold increase in amphetamine-stimulated hyperlocomotion was also measured in ABHD6 heterozygote mice and in WT mice treated with the ABHD6 inhibitor KT-182.
Reference: Cannabis Cannabinoid Res. 2022 Apr;7(2):188-198. https://pubmed.ncbi.nlm.nih.gov/34705543/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
43.9 |
100.00 |
| DMF |
10.0 |
22.80 |
| Ethanol |
11.0 |
25.08 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
438.53
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Manterola A, Bernal-Chico A, Cipriani R, Ruiz A, Pérez-Samartín A, Moreno-Rodríguez M, Hsu KL, Cravatt BF, Brown JM, Rodríguez-Puertas R, Matute C, Mato S. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis. Neuropharmacology. 2018 Oct;141:181-191. doi: 10.1016/j.neuropharm.2018.08.038. Epub 2018 Aug 30. PMID: 30171986.
2. Deng L, Viray K, Singh S, Cravatt B, Stella N. ABHD6 Controls Amphetamine-Stimulated Hyperlocomotion: Involvement of CB1 Receptors. Cannabis Cannabinoid Res. 2022 Apr;7(2):188-198. doi: 10.1089/can.2021.0066. Epub 2021 Oct 27. PMID: 34705543; PMCID: PMC9070749.
In vitro protocol:
1. Manterola A, Bernal-Chico A, Cipriani R, Ruiz A, Pérez-Samartín A, Moreno-Rodríguez M, Hsu KL, Cravatt BF, Brown JM, Rodríguez-Puertas R, Matute C, Mato S. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis. Neuropharmacology. 2018 Oct;141:181-191. doi: 10.1016/j.neuropharm.2018.08.038. Epub 2018 Aug 30. PMID: 30171986.
In vivo protocol:
1. Deng L, Viray K, Singh S, Cravatt B, Stella N. ABHD6 Controls Amphetamine-Stimulated Hyperlocomotion: Involvement of CB1 Receptors. Cannabis Cannabinoid Res. 2022 Apr;7(2):188-198. doi: 10.1089/can.2021.0066. Epub 2021 Oct 27. PMID: 34705543; PMCID: PMC9070749.
1: Manterola A, Bernal-Chico A, Cipriani R, Ruiz A, Pérez-Samartín A, Moreno- Rodríguez M, Hsu KL, Cravatt BF, Brown JM, Rodríguez-Puertas R, Matute C, Mato S. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis. Neuropharmacology. 2018 Oct;141:181-191. doi: 10.1016/j.neuropharm.2018.08.038. Epub 2018 Aug 30. PMID: 30171986.
2: Owens RA, Mustafa MA, Ignatowska-Jankowska BM, Damaj MI, Beardsley PM, Wiley JL, Niphakis MJ, Cravatt BF, Lichtman AH. Inhibition of the endocannabinoid- regulating enzyme monoacylglycerol lipase elicits a CB1 receptor- mediated discriminative stimulus in mice. Neuropharmacology. 2017 Oct;125:80-86. doi: 10.1016/j.neuropharm.2017.06.032. Epub 2017 Jun 30. PMID: 28673548; PMCID: PMC5771234.
3: Tanaka M, Moran S, Wen J, Affram K, Chen T, Symes AJ, Zhang Y. WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism. J Neuroinflammation. 2017 Jan 10;14(1):7. doi: 10.1186/s12974-016-0783-4. PMID: 28086912; PMCID: PMC5234251.
4: Hsu KL, Tsuboi K, Chang JW, Whitby LR, Speers AE, Pugh H, Cravatt BF. Discovery and optimization of piperidyl-1,2,3-triazole ureas as potent, selective, and in vivo-active inhibitors of α/β-hydrolase domain containing 6 (ABHD6). J Med Chem. 2013 Nov 14;56(21):8270-9. doi: 10.1021/jm400899c. Epub 2013 Oct 23. PMID: 24152295; PMCID: PMC3987869.
